Skip to main content

Table 1 Patient and tumor characteristics according to the addition of bevacizumab to first-line systemic therapy (n = 361)

From: Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

N = 361 Without bevacizumab (n = 176) With bevacizumab (n = 185)   Combination chemotherapy (n = 219) Single-agent chemotherapy (n = 142)  
  N (%) N (%) P-value N (%) N (%) P-value
Gender      0.69      0.33
 Male 75 (43) 72 (41)   126 (58) 89 (63)  
 Female 101 (57) 113 (59)   93 (42) 53 (37)
Age (years)      <0.0001      <0.0001
  < 60 36 (20) 57 (31)   71 (32) 24 (17)  
 60–75 91 (52) 111 (60)   128 (59) 72 (51)
  ≥ 75 49 (28) 17 (9)   20 (9) 46 (32)
Comorbidity      <0.001      <0.01
 No 50 (28) 81 (44)   38 (28) 91 (42)  
 1 comorbid condition 49 (28) 56 (30)   36 (26) 66 (30)
  ≥ 2 comorbid conditions 63 (36) 33 (18)   52 (36) 44 (20)
 Unknown 14 (8) 15 (8)   14 (19) 18 (8)
Primary tumor localization      0.13     
 Rectum 68 (39) 85 (46)   107 (49) 47 (33) <0.01
 Colon 108 (61) 100 (54)   112 (51) 95 (67)  
Adjuvant chemotherapy      0.34      <0.01
 No 103 (59) 100 (54)   137 (63) 67 (47)  
 Yes 73 (41) 85 (46)   82 (37) 75 (53)
Time to metastases (years)      0.12      0.59
  < 1 year 57 (32) 43 (23)   57 (26) 42 (30)  
 1–2 years 56 (32) 71 (38)   82 (37) 46 (32)
  ≥ 2 years 63 (36) 71 (38)   80 (37) 54 (38)
Period of diagnosis metastases      <0.01      0.81
 2005–2006 70 (40) 41 (22)   69 (31) 42 (30)  
 2007–2008 57 (32) 78 (42)   83 (38) 52 (37)
 2009–2011 49 (28) 66 (36)   67 (31) 48 (34)
Number of organs affected      0.29      0.39
 1 organ 72 (41) 85 (46)   92 (42) 65 (46)  
 2 organs 69 (39) 59 (32)   83 (38) 44 (31)
  ≥ 3 organs 35 (20) 41 (22)   44 (20) 33 (23)
First-line chemotherapy      <0.0001      
 Single agent chemotherapy 110 (63) 32 (27)      
 Combination chemotherapy 66 (37) 153 (83)
Bevacizumab           <0.0001
 Yes       153 (70) 32 (23)  
 No       66 (30) 110 (77)